Abstracts Archive - Page 1893 of 2425 - ACR Meeting Abstracts

Abstract Number: 2410 • 2014 ACR/ARHP Annual Meeting
Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort
Bindee Kuriya¹, Daming Lin², Cheryl Barnabe³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, Shahin Jamal⁷, J. Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Edward Keystone¹¹ and Vivian P. Bykerk¹², ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Rheumatology, Vancouver Coastal Health, Vancouver, BC, Canada, ⁸Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Medicine, Western University, London, ON, Canada, ¹¹University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ¹²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: To describe working status in an ERA population in the first year of disease, and factors associated with improved work productivity. Methods: Patients in…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2412 • 2014 ACR/ARHP Annual Meeting
Regime of Use of Rituximab in Patients with Rheumatoid Arthritis in Daily Clinical Practice
Leticia Merino-Meléndez¹, Irene Llorente², Santos Castañeda³, Teresa Velasco², Luis Sala-Icardo⁴, Rosario Garcia-Vicuña⁴, Alberto Garcia-Vadillo⁵, Juan P. López-Bote⁴, Jorge López-López⁶, Federico Herrera⁶, Cecilia Muñoz-Calleja⁶, JM Álvaro-Gracia² and Isidoro González-Alvaro⁴, ¹Rheumatology Department, Hospital Universitario de La Princesa, Madrid, Spain, ²Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁵Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ⁶Immunology, Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: The recommended therapeutic regime for Rituximab (RTX) in Rheumatoid Arthritis (RA), according to prescribing information, includes two 1000-milligram infusions given two weeks apart, every…
Abstract Number: 2373 • 2014 ACR/ARHP Annual Meeting
Compliance in the Rheumatoid Arthritis Comparison of Active Therapies Trial: Triple Vs Etanercept
Sarah Leatherman¹, Hongsheng Wu^2,3, Edward Keystone⁴, Mary Brophy¹ and James O'Dell^5,6, ¹MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³Computer Science and Systems, Wentworth Institute of Technology, Boston, MA, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵VA Nebraska-Western Iowa Health Care System, Omaha, NE, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose In the 48-week, double-blinded, noninferiority RACAT trial, 353 methotrexate suboptimal responders were randomized to two treatment strategies, either the addition of sulfasalazine and hydroxychloroquine…
Abstract Number: 2374 • 2014 ACR/ARHP Annual Meeting
Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients
Jose Felix Restrepo¹, Inmaculada del Rincon², Emily Molina³, Daniel Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine/Clinical Immunology, UTHSCSA, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center, San Antonio, TX, ⁴Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁵Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality in rheumatoid arthritis (RA). CVD risk factor reduction, such as reducing…
Abstract Number: 2375 • 2014 ACR/ARHP Annual Meeting
Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?
Huifeng Yun¹, Lang Chen², George W. Reed³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Corrona, LLC., Southborough, MA, ⁴Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁵Rheumatology, New York University School of Medicine, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) and biologic disease-modifying antirheumatic drugs (DMARDs) have previously been associated with serious infection events (SIEs) among rheumatoid arthritis (RA) patients. For patients…
Abstract Number: 2376 • 2014 ACR/ARHP Annual Meeting
Safety of Rapid Rituximab Infusion in Rheumatoid Arthritis in a Single Community Practice
Rafat Faraawi¹, Kelly Roth² and Sameeka Malik³, ¹564 Belmont Avenue West, K-W Musculoskeletal Research Inc, Kitchener, ON, Canada, ²K-W Musculoskeletal Research Inc., Kitchener, ON, Canada, ³KW Musculoskeletal Research Inc., Kitchener, ON, Canada
Background/Purpose: Rituximab, a chimeric monoclonal anti-CD20 antibody, is approved to be infused over 4 hours and 15 minutes (first infusion), and 3 hours and 15…
Abstract Number: 2377 • 2014 ACR/ARHP Annual Meeting
A Pilot Randomized Controlled Trial of a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients
Pip Aimer¹, Gareth Treharne², Simon Stebbings³, Christopher Frampton⁴, Vicky Cameron¹, Sandra Kirby⁵ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Psychology, University of Otago, Dunedin, New Zealand, ³Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵Arthritis New Zealand, Wellington, New Zealand
Background/Purpose Smoking adversely influences comorbidities in rheumatoid arthritis (RA) and may affect progression of RA. The combination of negative health effects makes a compelling case…
Abstract Number: 2378 • 2014 ACR/ARHP Annual Meeting
Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 Months Despite Infrequent Use of Biologic Therapies
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Sharon Dowell⁴, Luis R. Espinoza⁵, Edward Treadwell⁶, Theresa Lawrence-Ford⁷, Yvonne Sherrer⁸, Angelia Mosley-WIlliams⁹, Rodolfo Perez Alamino¹⁰, Ignacio Garcia-Valladares¹¹, Akgun Ince¹², Mercedes Quinones¹³, Chunqiao Luo³, Adrian Godoy⁴ and John Amatruda¹⁴, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁴Division of Rheumatology, Howard University, Washington, DC, ⁵Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁶Dept Medicine Div of Rheum, E Carolina Univ Sch of Med, Greenville, NC, ⁷North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁸Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁹Rheumatology, Detroit VAMC, Detroit, MI, ¹⁰internal Medicine, LSUHSC, New Orleans, LA, ¹¹Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ¹²Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹³Division of Rheumatology, Howard University Hospital, Washington, DC, ¹⁴Rheumatology, Howard University, Washington, DC
Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 months Despite Infrequent Use of Biologic Therapies. Background/Purpose: Ethnic minorities with rheumatoid arthritis…
Abstract Number: 2379 • 2014 ACR/ARHP Annual Meeting
Minimal Radiographic Progression in RA Patients Receiving Routine Care in the Espoir Early Arthritis Cohort: Similar Prognosis According to 6 Different Remission Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Nancy University Hospital, Nancy, France, ⁵Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose Remission has become a more achievable goal in rheumatoid arthritis (RA). Several criteria for remission are available in RA, including one based on RAPID3…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 2381 • 2014 ACR/ARHP Annual Meeting
Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice?
Christian A. Waimann¹, Gustavo Citera², Fernando Dal Pra³, Maria Celeste Orozco⁴, Federico Ceccatto⁵, Sergio Paira⁶, M Gauna⁷, Anastasia Secco⁷, M Mamani⁷, Lucila Marino⁸, Francisco Caeiro⁹, AC Alvarez¹⁰, Maria Haye Salinas⁹, L Encinas¹¹, Javier Rosa¹², Valeria Scaglioni¹³, Enrique R. Soriano¹⁴, Josefina Marcos¹⁵, Mercedes García¹⁵, A Salas¹⁵, Alejandro Martinez¹⁶, Rafael Chaparro del Moral¹⁷, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Veloso¹⁹, Ricardo V. Juárez²⁰, Maria Elena Crespo²¹, Ana Quinteros²², M Leal²², Gabriela Salvatierra²³, C Ledesma²³, Mónica P. Sacnun²⁴, R Quintana²⁵ and Marcelo Abdala²⁶, ¹Rheumatology, Hospital Olavarria, Olavarria, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Jose María Cullen, Santa Fé, Argentina, ⁶Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁷Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁰Hospital Privado Centro Médico de, Córdoba, Argentina, ¹¹Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹³Rheumatology Unit, Internal Medical Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁵HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁷Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁸Centro Medico Privado de Reumatologia, Tucumán, Argentina, ¹⁹Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ²⁰Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ²¹Hospital Señor Del Milagro, Salta, Argentina, ²²Centro Integral de Reumatología, Tucumán, Argentina, ²³Instituto Provincial De Rehabilitación Integral, Stgo. del Estero, Argentina, ²⁴Hospital Provincial, Rosario, Argentina, ²⁵Hospital provincial, Rosario, Argentina, ²⁶Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose : The treat-to-target (T2T) strategy has become the new paradigm for the treatment of Rheumatoid Arthritis (RA); however the question is whether this strategy…
Abstract Number: 2382 • 2014 ACR/ARHP Annual Meeting
Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures
Annelieke Pasma¹, Ethan den Boer², Adriaan van 't Spijker³, Reinier Timman³, Jan van Busschbach³ and J.M.W. Hazes⁴, ¹Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose Non-adherence to DMARDs is an important indicator for the effectiveness of treatment in early arthritis patients. Reported non-adherence rates differ widely, because studies use…
Abstract Number: 2383 • 2014 ACR/ARHP Annual Meeting
The 12-Years Retention Rate of the First-Line TNF-Inhibitor in the Treatment of Rheumatoid Arthritis: Real-Life Data from a Local Registry
Ennio Giulio Favalli¹, Martina Biggioggero², Francesca Pregnolato³, Andrea Becciolini², Alessandra Emiliana Penatti², Antonio Marchesoni⁴ and Pier Luigi Meroni², ¹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ³Experimental Laboratory of Immunological and Rheumatologic Researches, IRCCS, Istituto Auxologico Italiano, Milan, Italy, ⁴Rheumatology, Department of Rheumatology, Gaetano Pini Institute, Milan, Italy
Background/Purpose Data on over-10-years drug survival of TNF inhibitors (TNFi) are still lacking. The aim of the study is to analysed the long-term retention rate…
Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].